AstraZeneca – Daiichi $6.9B Pact To Co-develop Cancer ADC
Posted by
www.biotecnika.org
AstraZeneca – Daiichi $6.9B Pact To Co-develop Cancer ADC AstraZeneca
will enter a pcct worth $6.9 billion to co-develop Daiichi Sankyo's
Trastuzumab deruxtecan–just months prior to the initial application to
market the cancer-fighting antibody-drug conjugate (ADC) is defined to
be submitted to the FDA. Daiichi Sankyo is developing trastuzumab
deruxtecan, also called DS-8201, for individuals […]
The post AstraZeneca – Daiichi $6.9B Pact To Co-develop Cancer ADC
appeared first on BioTecNika .
https://www.biotecnika.org/2019/04/astrazeneca-daiichi-6-9b-pact/
Biotech News
Subscribe to:
Post Comments (Atom)
Post a Comment